I expect similar announcements from AstraZeneca and Moderna this week.

But fams, if you’re going to juice stocks, at least hit us with some data. Just a chart or a bar graph. A few confidence intervals. I don’t want much.
To the folks replying, "But the study has 43,538 participants..."

That's the number of enrollees overall. This current release involves 94 cases.

Pfizer will need two months of data on half of the overall enrollees before it can file for an EUA, which it expects by late Nov.
Indeed, if they were talking about 94 cases out of ~40,000 individuals (or even ~20,000 individuals), the efficacy would be greater than 99% (rather than the reported 90%).
https://twitter.com/MoNscience/status/1325780280263667713?s=20
https://twitter.com/MoNscience/status/1325782625663946752?s=20
https://twitter.com/MoNscience/status/1325785090618662912?s=20
https://twitter.com/MoNscience/status/1325789019595173888?s=20
Last note: I can understand why a company might release prelim data on an approved drug (e.g., an antiviral or steroid) that can be immediately repurposed for sick patients...
But if this vaccine candidate can't be made available (i.e. be considered for an EUA) until two months of data exist for half the participants...and if they're expecting to reach that milestone two weeks from now...then why put out this press release with incomplete data?
https://twitter.com/MoNscience/status/1325926711867764736
https://twitter.com/MoNscience/status/1325927216778153984?s=20
https://twitter.com/MoNscience/status/1325927840777342977?s=20
https://twitter.com/MoNscience/status/1325928459130957825?s=20
You can follow @MoNscience.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.